Auf dieser Seite
PDSB PDS Biotechnology Corporation - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 13, 2026
$0,75
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$0,2052-Wochen-Tief
$1,5552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$42M
P/E
-1.0
EPS
$-0.74
Ihre Abzeichen
52W-Spanne
$0–$2
Analystenbewertung
BUY
Kursziel
$5
P/E
-1.0
ROE
·
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
PDSB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$0.75
Marktkapitalisierung (MRQ)
$42M
P/E
-1.0
EPS
$-0.74
52W-Spanne
$0–$2
PDSB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 18. März 2019 | 1-for-20 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-0.742020-12-31 → 2025-12-31
Freier Cashflow·2016-12-31 → 2024-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | PDSB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -1.05-Jahres-Durchschnitt ≈-5.5 | ≈-5.5 | · | · | |
| K/B (MRQ) | -11.75-Jahres-Durchschnitt ≈4.4 | ≈4.4 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 4.65-Jahres-Durchschnitt ≈5.4 | ≈5.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | PDSB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 0.65-Jahres-Durchschnitt ≈8.3 | ≈8.3 | 3.7 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
10.0%
Nächster Bericht
Nov 11, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 13, 2026 | $-0.18 | $-0.13 | -35.7% |
| 31. März 2026 | Mai 13, 2026 | $-0.13 | $-0.15 | 15.0% |
| 31. Dezember 2025 | $-0.15 | $-0.19 | 24.4% | |
| 30. September 2025 | $-0.19 | $-0.22 | 12.7% | |
| 30. Juni 2025 | $-0.21 | $-0.24 | 11.8% | |
| 31. März 2025 | $-0.21 | $-0.25 | 16.5% | |
| 31. Dezember 2024 | $-0.21 | $-0.28 | 25.6% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $19M | $23M | $28M | $29M | $11M | $8M | $6M | $830.7K | $34M | $25M | $18M | $8M | |
| SG&A Expense | $13M | $14M | $15M | $12M | $10M | $7M | $11M | $3M | $18M | $15M | $9M | $5M | |
| Operating Expenses | $32M | $36M | $43M | $42M | $21M | $15M | $21M | $4M | $52M | $40M | $26M | $13M | |
| Operating Income | $-32M | $-36M | $-43M | $-42M | $-21M | $-15M | $-21M | $-4M | $-52M | $-40M | $-26M | $-13M | |
| Interest Expense | · | · | $4M | $1M | $0 | $0 | $33.6K | $3.6K | $2M | $1M | $816.5K | $183.2K | |
| Interest Income | $1M | $3M | $3M | $935.2K | $4.3K | $55.0K | $353.5K | $0 | · | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | $-190.3K | · | · | · | · | |
| Pretax Income | $-36M | $-38M | $-44M | $-42M | $-21M | $-15M | $-7M | $-4M | $-53M | $-41M | $-29M | $-13M | |
| Income Tax | $-1M | $-869.2K | $-1M | $-1M | $-5M | $0 | $-381.5K | $0 | $-3M | $-2M | $-1M | $-590.7K | |
| Net Income | $-34M | $-38M | $-43M | $-41M | $-17M | $-15M | $-7M | $-4M | $-51M | $-39M | $-28M | $-12M | |
| EPS (Basic) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | · | · | · | · | · | · | |
| Shares (Basic) | 46,384,280 | 36,452,707 | 30,952,060 | 28,599,221 | 25,597,125 | 16,745,044 | · | · | · | · | · | · | |
| Shares (Diluted) | 46,384,280 | 36,452,707 | 30,952,060 | 28,599,221 | 25,597,125 | 16,745,044 | · | · | · | · | · | · | |
| EBITDA | · | $-36M | $-43M | · | $-21M | $-15M | $-21M | $-43M | $-52M | $-40M | $-26M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $42M | $57M | $74M | $65M | $29M | $12M | $103.7K | $88M | $106M | $130M | $14M | |
| Prepaid Expense | $2M | $3M | $2M | $3M | $2M | $1M | $2M | $18.4K | $986.7K | $954.6K | $1M | $213.0K | |
| Current Assets | $28M | $45M | $59M | $76M | $67M | $30M | $14M | $122.1K | $89M | $107M | $131M | $15M | |
| PP&E (Net) | $120.2K | $142.0K | $134.1K | $0 | $86 | $5.4K | $21.1K | $29.5K | $3M | $3M | $3M | $1M | |
| PP&E (Gross) | $295.9K | $295.9K | $266.9K | $115.4K | $115.4K | $115.4K | $115.4K | $101.8K | $4M | $4M | $3M | $1M | |
| Accum. Depreciation | $175.7K | $153.9K | $132.8K | $115.4K | $115.3K | $110.0K | $94.4K | $72.3K | $305.3K | $122.4K | $91.4K | $38.3K | |
| Intangibles | · | · | · | · | · | $3M | $3M | $0 | · | · | · | · | |
| Other Non-current Assets | · | · | · | · | · | · | $0 | $12.8K | $142.9K | $142.9K | $55.2K | $55.2K | |
| Total Assets | $30M | $45M | $59M | $77M | $67M | $31M | $14M | $164.4K | $93M | $111M | $134M | $17M | |
| Accounts Payable | $4M | $2M | $7M | $1M | $1M | $1M | $1M | $1M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $742.2K | $3M | $2M | $8M | $2M | $2M | $1M | $601.9K | $5M | $3M | $4M | $2M | |
| Current Liabilities | $9M | $17M | $14M | $10M | $4M | $3M | $3M | $2M | $13M | $7M | $9M | $4M | |
| Capital Leases | · | · | $0 | $0 | $231.4K | $490.4K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | · | · | · | · | |
| Total Liabilities | $21M | $26M | $33M | $33M | $4M | $4M | $3M | $2M | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $5M | · | |
| Common Stock | $18.1K | $12.5K | $10.9K | $10.0K | $9.4K | $7.3K | $1.7K | $1.1K | $10.4K | $9.8K | $9.7K | $770 | |
| Paid-in Capital | $226M | $201M | $171M | $146M | $124M | $71M | $41M | $20M | $214M | $190M | · | · | |
| Retained Earnings | $-217M | $-182M | $-145M | $-102M | $-61M | $-44M | $-29M | $-22M | $-152M | $-101M | $-62M | $-30M | |
| Stockholders' Equity | $9M | $19M | $26M | $44M | $63M | $27M | $12M | $-2M | $-609.5K | $89M | $122M | $-28M | |
| Liabilities + Equity | $30M | $45M | $59M | $77M | $67M | $31M | $14M | $164.4K | $93M | $111M | $134M | $17M | |
| Shares Outstanding | 54,878,233 | 37,987,380 | 33,094,521 | 30,170,317 | 28,448,612 | 22,261,619 | 5,281,237 | 3,417,187 | 30,869,205 | 28,918,516 | 28,810,845 | 1,688,475 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $15.6K | $98.4K | $69.1K | · | · | · | · | |
| Stock-based Comp | $4M | $7M | $8M | $5M | $4M | $432.3K | $3M | $866.8K | $6M | $5M | $3M | $1M | |
| Deferred Tax | · | · | · | · | · | $0 | $-381.5K | $0 | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | $2M | $10M | $0 | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | $-14M | · | · | · | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-34M | $-26M | $-12M | $-13M | $-18M | $-2M | $-41M | $-32M | $-22M | $-10M | |
| CapEx | $0 | $29.0K | $0 | · | · | · | · | $0 | $188.7K | $686.7K | $1M | $884.8K | |
| Investing Cash Flow | $0 | $-29.0K | $0 | · | · | $0 | $29M | $0 | $-188.7K | $-686.7K | $-1M | · | |
| Stock Issued | $10M | $0 | $16M | $10M | $49M | $30M | $750.0K | $1M | · | · | · | · | |
| Net Stock Activity | · | $23M | $16M | · | $49M | $30M | $750.0K | · | · | · | · | · | |
| Financing Cash Flow | $13M | $20M | $16M | $34M | $49M | $30M | $750.0K | $1M | $23M | $9M | $140M | · | |
| Net Change in Cash | · | · | · | · | · | · | · | $-53M | $-18M | $-24M | $116M | $6M | |
| Taxes Paid | $-1M | $-924.2K | · | · | · | · | $0 | $500 | · | · | · | · | |
| Free Cash Flow | · | $-35M | · | · | · | · | · | $-33M | $-41M | $-33M | $-23M | · | |
| Levered FCF | · | · | · | · | · | · | · | $-34M | $-43M | $-34M | $-24M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -71.8% | -63.0% | · | -34.5% | -65.4% | -95.5% | -63.4% | -50.0% | -31.7% | -37.2% | · | |
| ROE | · | -183.4% | -169.7% | · | -25.8% | -51.1% | -51.3% | -284.2% | -67.1% | -36.7% | -59.3% | · | |
| ROIC | · | -186.8% | -159.5% | · | -26.8% | -54.9% | -189.1% | -135.2% | -79.3% | -42.2% | -20.8% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 2.6 | 4.3 | · | 17.8 | 9.3 | 5.2 | 5.6 | 6.9 | 16.1 | 15.3 | · | |
| Quick Ratio | · | 2.4 | 4.1 | · | 17.4 | 8.8 | 4.4 | 5.4 | 6.8 | 15.9 | 15.2 | · | |
| Interest Coverage | · | · | -10.2 | · | · | · | -626.8 | -30.2 | -23.8 | -32.8 | -32.5 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $0.50 | $0.79 | · | $2.22 | $1.22 | $2.21 | $0.95 | $2.02 | $3.09 | $4.25 | · | |
| Cash Flow / Share | · | $-0.96 | $-1.09 | · | $-0.49 | · | · | · | · | · | · | · | |
| Cash / Share | · | $1.10 | $1.71 | · | $2.29 | $1.30 | $2.30 | $1.10 | $2.85 | $3.68 | $4.52 | · | |
| EPS (TTM) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-34M | $-38M | $-43M | $-41M | $-17M | $-15M | $-7M | $-4M | $-51M | $-39M | $-28M | · | |
| Market Cap | · | $62M | $164M | · | $230M | $48M | $14M | $202M | $5.78B | $7.23B | $7.20B | · | |
| P/E | -1.0 | -1.6 | -3.6 | -9.2 | -12.3 | -2.4 | · | · | · | · | · | · | |
| P/B | · | 3.3 | 6.3 | · | 3.6 | 1.8 | 1.2 | 6.8 | 92.7 | 81.0 | 58.8 | · | |
| P / Tangible Book | 4.6 | 3.3 | 6.3 | 9.1 | 3.6 | 2.0 | · | · | · | · | · | · | |
| P / Cash Flow | · | -1.8 | -4.9 | · | -18.5 | -3.6 | -0.8 | -6.1 | -142.1 | -224.6 | -331.1 | · | |
| P / FCF | · | -1.8 | · | · | · | · | · | -6.1 | -141.5 | -219.9 | -312.4 | · | |
| Earnings Yield | -96.1% | -63.2% | -28.0% | -10.8% | -8.2% | -41.6% | · | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $3M | $3M | $4M | $5M | $4M | $6M | $5M | $7M | $5M | $7M | $7M | $6M | $8M | $6M | $16M | $4M | |
| SG&A Expense | $3M | $3M | $2M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | |
| Operating Expenses | $6M | $7M | $7M | $8M | $8M | $9M | $7M | $10M | $9M | $10M | $10M | $11M | $13M | $9M | $19M | $7M | |
| Operating Income | $-6M | $-7M | $-7M | $-8M | $-8M | $-9M | $-7M | $-10M | $-9M | $-10M | $-10M | $-11M | $-13M | $-9M | $-19M | $-7M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $995.4K | $966.8K | $919.2K | $397.3K | |
| Interest Income | $125.4K | $186.8K | $224.7K | $281.1K | $333.6K | $377.8K | $503.9K | $666.8K | $675.2K | $668.9K | $683.5K | $739.4K | $750.7K | $729.3K | $602.9K | $252.1K | |
| Pretax Income | $-10M | $-7M | $-8M | $-9M | $-9M | $-10M | $-8M | $-11M | $-9M | $-11M | $-11M | $-11M | $-13M | · | $-19M | $-7M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $-1M | $0 | $0 | $-869.2K | $0 | $2 | $0 | $-1M | · | $0 | $0 | |
| Net Income | $-10M | $-7M | $-8M | $-9M | $-9M | $-8M | $-8M | $-11M | $-8M | $-11M | $-11M | $-11M | $-12M | $-10M | $-19M | $-7M | |
| EPS (Basic) | $-0.18 | $-0.13 | $-0.13 | $-0.19 | $-0.21 | $-0.21 | $-0.21 | $-0.29 | $-0.23 | $-0.30 | $-0.35 | $-0.35 | $-0.37 | $-0.32 | $-0.65 | $-0.26 | |
| EPS (Diluted) | $-0.18 | $-0.13 | $-0.13 | $-0.19 | $-0.21 | $-0.21 | $-0.21 | $-0.29 | $-0.23 | $-0.30 | $-0.35 | $-0.35 | $-0.37 | $-0.32 | $-0.65 | $-0.26 | |
| Shares (Basic) | 55,659,669 | 55,496,279 | · | 46,869,531 | 45,902,502 | 40,521,001 | · | 36,806,592 | 36,693,561 | 34,815,870 | · | 30,910,520 | 30,802,498 | 30,428,053 | · | 28,458,688 | |
| Shares (Diluted) | 55,659,669 | 55,496,279 | · | 46,869,531 | 45,902,502 | 40,521,001 | · | 36,806,592 | 36,693,561 | 34,815,870 | · | 30,910,520 | 30,802,498 | 30,428,053 | · | 28,458,688 | |
| EBITDA | $-6M | $-7M | · | $-8M | $-8M | $-9M | · | $-10M | $-9M | $-10M | · | $-11M | $-13M | $-9M | · | $-7M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6M | $22M | $27M | $26M | $32M | $40M | $42M | $50M | $58M | $67M | $57M | $54M | $61M | $65M | $74M | $72M | |
| Prepaid Expense | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | |
| Current Assets | $7M | $23M | $28M | $28M | $34M | $42M | $45M | $52M | $60M | $69M | $59M | $57M | $63M | $68M | $76M | $74M | |
| PP&E (Net) | $176.6K | $114.7K | $120.2K | $125.6K | $131.1K | $136.6K | $142.0K | $147.5K | $152.9K | $129.4K | $134.1K | $138.9K | $143.6K | $148.3K | $0 | $0 | |
| PP&E (Gross) | · | · | $295.9K | · | · | · | $295.9K | · | · | · | $266.9K | · | · | · | $115.4K | · | |
| Accum. Depreciation | · | · | $175.7K | · | · | · | $153.9K | · | · | · | $132.8K | · | · | · | $115.4K | · | |
| Total Assets | $9M | $25M | $30M | $35M | $40M | $47M | $45M | $52M | $60M | $69M | $59M | $57M | $64M | $68M | $77M | $75M | |
| Accounts Payable | $6M | $4M | $4M | $5M | $4M | $3M | $2M | $1M | $3M | $6M | $7M | $5M | $4M | $2M | $1M | $2M | |
| Accrued Liabilities | $2M | $1M | $742.2K | $2M | $1M | $3M | $3M | $4M | $2M | $2M | $2M | $4M | $3M | $2M | $8M | $2M | |
| Current Liabilities | $12M | $10M | $9M | $13M | $12M | $18M | $17M | $18M | $16M | $15M | $14M | $9M | $8M | $4M | $10M | $5M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Total Liabilities | $12M | $21M | $21M | $25M | $25M | $25M | $26M | $30M | $30M | $32M | $33M | $33M | $31M | $27M | $33M | $28M | |
| Common Stock | $18.5K | $18.4K | $18.1K | $15.7K | $15.4K | $15.0K | $12.5K | $12.2K | $12.1K | $12.1K | $10.9K | $10.2K | $10.2K | $10.1K | $10.0K | $9.4K | |
| Paid-in Capital | $230M | $228M | $226M | $218M | $216M | $213M | $201M | $196M | $194M | $192M | $171M | $158M | $155M | $152M | $146M | $129M | |
| Retained Earnings | $-234M | $-224M | $-217M | $-209M | $-200M | $-191M | $-182M | $-174M | $-163M | $-155M | $-145M | $-134M | $-123M | $-111M | $-102M | $-82M | |
| Stockholders' Equity | $-4M | $4M | $9M | $9M | $16M | $22M | $19M | $22M | $31M | $37M | $26M | $24M | $32M | $41M | $44M | $47M | |
| Liabilities + Equity | $9M | $25M | $30M | $35M | $40M | $47M | $45M | $52M | $60M | $69M | $59M | $57M | $64M | $68M | $77M | $75M | |
| Shares Outstanding | 55,921,806 | 55,815,653 | 54,878,233 | 47,705,442 | 46,633,362 | 45,445,851 | 37,987,380 | 36,819,810 | 36,779,275 | 36,679,275 | 33,094,521 | 31,007,763 | 30,868,188 | 30,723,610 | 30,170,317 | 28,458,688 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $448.0K | $1M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $1M | $1M | |
| Operating Cash Flow | $-3M | $-4M | $-4M | $-6M | $-9M | $-9M | $-8M | $-8M | $-9M | $-10M | $-8M | $-7M | $-5M | $-13M | $-8M | $-6M | |
| CapEx | · | · | $0 | $0 | · | · | $0 | $1 | · | · | $0 | $0 | · | · | · | · | |
| Investing Cash Flow | · | · | $0 | $0 | · | · | $0 | $-1 | · | · | $0 | $0 | · | · | · | · | |
| Stock Issued | $0 | $0 | $3M | $0 | $0 | $7M | $0 | $-19M | $0 | $0 | $11M | $800.0K | $200.0K | $5M | $10M | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $7M | · | · | $0 | $19M | · | $800.0K | $200.0K | $5M | · | · | |
| Financing Cash Flow | $-13M | $-679.8K | $4M | $241.2K | $995.9K | $7M | $172.8K | $17.2K | $-13.8K | $20M | $11M | $802.3K | $240.0K | $5M | $10M | $25M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -39.6% | -20.5% | · | -20.7% | -18.7% | -14.6% | · | -19.6% | -13.4% | -15.4% | · | -16.4% | -19.3% | -14.9% | · | -10.1% | |
| ROE | -157.5% | -56.0% | · | -57.3% | -40.2% | -28.5% | · | -46.2% | -26.3% | -27.1% | · | -30.3% | -27.5% | -19.9% | · | -12.9% | |
| ROIC | 181.5% | -167.5% | · | -86.1% | -47.8% | -35.8% | · | -46.3% | -25.4% | · | · | -43.0% | -34.9% | · | · | -15.5% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.3 | · | 2.1 | 2.9 | 2.3 | · | 2.8 | 3.8 | 4.6 | · | 6.2 | 8.0 | 16.5 | · | 15.4 | |
| Quick Ratio | 0.5 | 2.1 | · | 2.0 | 2.8 | 2.2 | · | 2.7 | 3.7 | 4.4 | · | 5.9 | 7.7 | 15.8 | · | 14.8 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -8.6 | · | -9.8 | -12.8 | -9.7 | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.06 | $0.07 | · | $0.20 | $0.34 | $0.49 | · | $0.60 | $0.84 | $1.01 | · | $0.79 | $1.05 | $1.33 | · | $1.65 | |
| Cash Flow / Share | · | $-0.08 | · | · | · | $-0.22 | · | · | · | $-0.29 | · | · | · | $-0.43 | · | · | |
| Cash / Share | $0.10 | $0.39 | · | $0.55 | $0.68 | $0.88 | · | $1.35 | $1.57 | $1.82 | · | $1.75 | $1.96 | $2.12 | · | $2.52 | |
| EPS (TTM) | $-0.63 | $-0.66 | · | $-0.82 | $-0.92 | $-0.94 | · | $-1.17 | $-1.23 | $-1.37 | · | $-1.69 | $-1.60 | $-1.43 | · | $-1.03 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-34M | $-33M | · | $-35M | $-37M | $-35M | · | $-41M | $-41M | $-44M | · | $-51M | $-48M | $-42M | · | $-28M | |
| Market Cap | $49M | $34M | · | $48M | $62M | $54M | · | $141M | $108M | $145M | · | $157M | $155M | $189M | · | $85M | |
| P/E | -1.4 | -0.9 | · | -1.2 | -1.4 | -1.3 | · | -3.3 | -2.4 | -2.9 | · | -3.0 | -3.1 | -4.3 | · | -2.9 | |
| P/B | -13.8 | 8.7 | · | 5.1 | 3.9 | 2.4 | · | 6.4 | 3.5 | 3.9 | · | 6.4 | 4.8 | 4.6 | · | 1.8 | |
| P / Tangible Book | · | 8.7 | · | 5.1 | 3.9 | 2.4 | · | 6.4 | 3.5 | 3.9 | · | 6.4 | 4.8 | 4.6 | · | 1.8 | |
| P / Cash Flow | · | -7.7 | · | · | · | -6.0 | · | · | · | -14.6 | · | · | · | -14.3 | · | · | |
| Earnings Yield | -71.5% | -109.1% | · | -81.2% | -69.2% | -79.0% | · | -30.6% | -42.0% | -34.6% | · | -33.5% | -31.8% | -23.2% | · | -34.7% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-34M | $-38M | $-43M | $-41M | $-17M |
| Verwässerte EPS | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | · | 2.6 | 4.3 | · | 17.8 |
| Quick Ratio | · | 2.4 | 4.1 | · | 17.4 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | · | $-35M | · | · | · |
Institutionelle Eigentümer (13F) 55 Einreicher · $8.6M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
55
Gehaltener Wert
$8.6M
Neue Positionen
14
Geschlossene Positionen
4
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 14 (+5 vs. Vorquartal) | 4 (-5 vs. Vorquartal) | 14 (+3 vs. Vorquartal) | 7 (-2 vs. Vorquartal) | +2.7M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.502.228 | 1.950.946 | 17,40% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.497.097 | 1.699.315 | 17,34% | Aktien |
| Quantinno Capital Management LP | $565.822 | 642.177 | 6,55% | Aktien |
| Focus Partners Wealth | $565.822 | 642.177 | 6,55% | Aktien |
| BlackRock, Inc. | $535.391 | 607.639 | 6,20% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $517.410 | 587.139 | 5,99% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $314.644 | 357.144 | 3,64% | Aktien |
| Militia Capital Management LLC | $292.349 | 331.800 | 3,39% | Aktien |
| CITADEL ADVISORS LLC | $285.301 | 323.801 | 3,30% | Aktien |
| Caption Management, LLC | $281.159 | 319.100 | 3,26% | Kaufoption |
| MORGAN STANLEY | $276.597 | 313.922 | 3,20% | Aktien |
| BLAIR WILLIAM & CO/IL | $264.330 | 300.000 | 3,06% | Aktien |
| JANE STREET GROUP, LLC | $246.412 | 279.664 | 2,85% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $222.213 | 252.200 | 2,57% | Aktien |
| INSPIRION WEALTH ADVISORS, LLC | $165.182 | 188.995 | 1,91% | Aktien |
| MARSHALL WACE, LLP | $129.510 | 147.171 | 1,50% | Aktien |
| STATE STREET CORP | $117.480 | 133.333 | 1,36% | Aktien |
| NORTHERN TRUST CORP | $111.461 | 126.502 | 1,29% | Aktien |
| WELLS FARGO & COMPANY/MN | $96.040 | 109.000 | 1,11% | Aktien |
| COMMONWEALTH EQUITY SERVICES, LLC | $81.940 | 92.997 | 0,95% | Aktien |
| Iron Gate Global Advisors LLC | $62.035 | 70.406 | 0,72% | Aktien |
| Bank of New York Mellon Corp | $60.348 | 68.491 | 0,70% | Aktien |
| Watts Gwilliam & Co., LLC | $55.550 | 55.000 | 0,64% | Aktien |
| Tempus Wealth Planning, LLC | $54.452 | 61.800 | 0,63% | Aktien |
| TWO SIGMA SECURITIES, LLC | $36.470 | 41.391 | 0,42% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.009 | 36.328 | 0,37% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $29.798 | 33.819 | 0,35% | Aktien |
| XTX Topco Ltd | $29.163 | 33.098 | 0,34% | Aktien |
| OSAIC HOLDINGS, INC. | $26.433 | 30.000 | 0,31% | Aktien |
| ACT CAPITAL MANAGEMENT, LLC | $26.433 | 30.000 | 0,31% | Aktien |
| Rockefeller Capital Management L.P. | $24.375 | 27.664 | 0,28% | Aktien |
| CITADEL ADVISORS LLC | $21.587 | 24.500 | 0,25% | Kaufoption |
| Federation des caisses Desjardins du Quebec | $17.444 | 19.800 | 0,20% | Aktien |
| Vanguard Global Advisers, LLC | $11.053 | 12.546 | 0,13% | Aktien |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | $10.573 | 12.000 | 0,12% | Aktien |
| PNC Financial Services Group, Inc. | $10.484 | 11.900 | 0,12% | Aktien |
| UBS Group AG | $9.798 | 11.121 | 0,11% | Aktien |
| GOLDMAN SACHS GROUP INC | $8.853 | 10.048 | 0,10% | Aktien |
| GRANDFIELD & DODD, LLC | $8.811 | 10.000 | 0,10% | Aktien |
| DAVENPORT & Co LLC | $8.811 | 10.000 | 0,10% | Aktien |
| Kathleen S. Wright Associates Inc. | $7.070 | 7.000 | 0,08% | Aktien |
| Tower Research Capital LLC (TRC) | $3.473 | 3.942 | 0,04% | Aktien |
| GROUP ONE TRADING LLC | $3.143 | 3.567 | 0,04% | Aktien |
| CREATIVE FINANCIAL DESIGNS INC /ADV | $2.643 | 3.000 | 0,03% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $1.776 | 2.000 | 0,02% | Aktien |
| Rialto Wealth Management, LLC | $671 | 761 | 0,01% | Aktien |
| Truvestments Capital LLC | $577 | 655 | 0,01% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $571 | 648 | 0,01% | Aktien |
| BARCLAYS PLC | $513 | 582 | 0,01% | Aktien |
| SBI Securities Co., Ltd. | $100 | 113 | 0,00% | Aktien |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Nant Capital, LLC, Patrick Soon-Shiong | 21. September 2026 | 19,90% | Erste Einreichung | Vorstandskampagne | SEC |
| NetScientific Plc, Melvin Lawson ×3 Einreichungen | 21. Juni 2021 | · | Erste Einreichung | Passive Anlage | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×3 Einreichungen | 28. März 2019 | · | Erste Einreichung | Passive Anlage | SEC |
| New Leaf Ventures III, L.P., New Leaf Biopharma Opportunities I, L.P., New Leaf Venture Associates III, L.P., New Leaf BPO Associates I, L.P., New Leaf Venture Management III, L.L.C., Vijay Lathi, Ronald Hunt, Liam Ratcliffe ×2 Einreichungen | 25. März 2019 | · | Erste Einreichung | Vorstandskampagne | SEC |
| Venrock Healthcare Capital Partners, L.P., Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings, LLC, VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Hove, Anders, Koh, Bong | 16. Oktober 2015 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 37 Insider · 20 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Frank Bedu-Addo | President/CEO | 12. Januar 2026 A | 690.866 | 0 | 0 | $0 |
| Brian A Leuthner | President and CEO | 15. März 2019 M | 239.268 | 0 | 0 | $0 |
| Lars Boesgaard | Chief Financial Officer | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Matthew C Hill | Chief Financial Officer | 5. Januar 2023 A | 4.075 | 0 | 0 | $0 |
| Seth Van Voorhees | Chief Financial Officer | 15. Juni 2021 P | 17.647 | 0 | 0 | $0 |
| Michael N. King | Interim CFO | 8. Dezember 2020 A | · | 0 | 0 | $0 |
| Andrew Saik | Chief Financial Officer | 14. Februar 2020 A | 42.549 | 0 | 0 | $0 |
| Andrew J. Einhorn | Chief Financial Officer | 1. März 2017 X | 43.223 | 0 | 0 | $0 |
| Stephan Toutain | Chief Operating Officer | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Daniel Brennan | Chief Operating Officer | 1. März 2018 A | · | 0 | 0 | $0 |
| Kirk V. Shepard | Chief Medical Officer | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Spencer D. Brown | Senior VP, General Counsel | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Gregory Conn | Chief Scientific Officer | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Lauren Wood | Chief Medical Officer | 5. Januar 2023 A | · | 0 | 0 | $0 |
| Bradford W Middlekauff | Senior VP, GC and Secretary | 15. März 2019 M | 59.766 | 0 | 0 | $0 |
| Alyssa Wyant | SVP Regulatory Affairs | 14. August 2018 A | · | 0 | 0 | $0 |
| Herbert J Faleck | Chief Medical Officer | 14. August 2018 A | 500 | 0 | 0 | $0 |
| Albert N Marchio II | Chief Accounting & Adm Officer | 14. August 2018 A | 0 | 0 | 0 | $0 |
| Alpaslan Yaman | V.P., Technical Ops. & Mfg. | 13. März 2017 A | · | 0 | 0 | $0 |
| Renu Vaish | V.P., Global Reg. Affairs | 16. Juni 2016 M | 5.350 | 0 | 0 | $0 |
| Ilian Iliev | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Kamil Ali-Jackson | Direktor | 12. Januar 2026 A | 11.764 | 0 | 0 | $0 |
| Gregory Gene Freitag | Direktor | 12. Januar 2026 A | 61.213 | 0 | 0 | $0 |
| Steve C Glover | Direktor | 12. Januar 2026 A | 78.851 | 0 | 0 | $0 |
| Otis W Brawley | Direktor | 12. Januar 2026 A | · | 0 | 0 | $0 |
| Richard Sykes | Direktor | 24. Juni 2024 A | 445.108 | 0 | 0 | $0 |
| James J Loughlin | Direktor | 28. Juni 2019 A | 26.625 | 0 | 0 | $0 |
| Loch R. Macdonald | Direktor | 15. März 2019 M | 580.602 | 0 | 0 | $0 |
| Liam Ratcliffe | Direktor | 15. März 2019 M | 10.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Direktor | 15. März 2019 M | 48.661 | 0 | 0 | $0 |
| Rosemary A Crane | Direktor | 15. März 2019 M | 10.000 | 0 | 0 | $0 |
| Sol J Barer | Direktor | 15. März 2019 M | 678.075 | 0 | 0 | $0 |
| Isaac Blech | Direktor | 15. März 2019 M | 10.000 | 0 | 0 | $0 |
| Kurt G Conti | Direktor | 23. März 2018 J | 0 | 0 | 0 | $0 |
| Dr. James I. Healy | Direktor | 20. Juni 2017 A | 2.852.711 | 0 | 0 | $0 |
| Anders D Hove | Direktor | 6. Oktober 2015 C | 2.068.582 | 0 | 0 | $0 |
| Delyle W Bloomquist | · | 16. Juni 2021 M | 193.888 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 3 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
PDSB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 9 Analysten
KAUF
Median-Ziel
$4.75
+534,6%
2 22,2%
Starker Kauf
6 66,7%
Kauf
1 11,1%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
2 Analysten · 2026-09-28Mittelwert-Ziel $4.75 +534,6%
← Unter allen Zielen
Aktueller Preis $0.75
Tief$4.50
Mittelwert$4.75
Hoch$5.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 13, 2026